Novel CSF β-synuclein-specific assays signal early synaptic degeneration in Alzheimer’s disease
Abstract Background Beta-synuclein (β-syn), measured at N-terminal epitopes, is an emerging cerebrospinal fluid (CSF) biomarker for synaptic degeneration in Alzheimer's disease (AD). Targeting the mid-region or C-terminus of β-syn may enhance analytical specificity due to the distinct structure...
Saved in:
| Main Authors: | Sherif Bayoumy, Julie Goossens, Charlotte De Rocker, Senna Y. Sie, Nolan J. Barrett, Wiesje M. van der Flier, Charlotte E. Teunissen, Eugeen Vanmechelen, Inge M. W. Verberk |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | Alzheimer’s Research & Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13195-025-01716-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Influence of co-pathology on CSF and plasma synaptic markers SNAP25 and VAMP2 in Alzheimer’s disease and Parkinson’s disease
by: Lorenzo Gaetani, et al.
Published: (2025-05-01) -
N-acetylation of α-synuclein enhances synaptic vesicle clustering mediated by α-synuclein and lysophosphatidylcholine
by: Chuchu Wang, et al.
Published: (2024-12-01) -
Synaptic protein CSF levels relate to memory scores in individuals without dementia
by: Kirsten E. J. Wesenhagen, et al.
Published: (2025-03-01) -
Dissection of blood–brain barrier dysfunction through CSF PDGFRβ and amyloid, tau, neuroinflammation, and synaptic CSF biomarkers in neurodegenerative disordersResearch in context
by: Agathe Vrillon, et al.
Published: (2025-05-01) -
Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
by: Rik Ossenkoppele, et al.
Published: (2021-07-01)